References
- UNODC. World drug report 2018. United Nations: United Nations Office on Drugs and Crime; 2018.
- G. B. D. Alcohol Drug Use (Collaborators). The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Psychiatry. 2018;5:987–1012. doi:https://doi.org/10.1016/S2215-0366(18)30337-7.
- Degenhardt L, Baxter AJ, Lee YY, Hall W, Sara GE, Johns N, Flaxman A, Whiteford HA, Vos T. The global epidemiology and burden of psychostimulant dependence: findings from the Global Burden of Disease Study 2010. Drug Alcohol Depend. 2014;137:36–47. doi:https://doi.org/10.1016/j.drugalcdep.2013.12.025.
- Huang MC, Yang SY, Lin SK, Chen KY, Chen YY, Kuo CJ, Hung YN. Risk of cardiovascular diseases and stroke events in methamphetamine users: a 10-year follow-up study. J Clin Psychiatry. 2016;77:1396–403. doi:https://doi.org/10.4088/JCP.15m09872.
- Shoptaw S, Reback CJ. Methamphetamine use and infectious disease-related behaviors in men who have sex with men: implications for interventions. Addiction. 2007;102:130–35. doi:https://doi.org/10.1111/j.1360-0443.2006.01775.x.
- Kuo CJ, Tsai SY, Liao YT, Conwell Y, Lin SK, Chang CL, Chen CC, Chen WJ. Risk and protective factors for suicide among patients with methamphetamine dependence: a nested case-control study. J Clin Psychiatry. 2011;72:487–93. doi:https://doi.org/10.4088/JCP.09m05360gry.
- Kuo CJ, Liao YT, Chen WJ, Tsai SY, Lin SK, Chen CC. Causes of death of patients with methamphetamine dependence: a record-linkage study. Drug Alcohol Rev. 2011;30:621–28. doi:https://doi.org/10.1111/j.1465-3362.2010.00255.x.
- Yang LH, Wong LY, Grivel MM, Hasin DS. Stigma and substance use disorders: an international phenomenon. Curr Opin Psychiatry. 2017;30:378–88. doi:https://doi.org/10.1097/YCO.0000000000000351.
- Hedden SL, Gfroerer JC. Correlates of perceiving a need for treatment among adults with substance use disorder: results from a national survey. Addict Behav. 2011;36:1213–22. doi:https://doi.org/10.1016/j.addbeh.2011.07.026.
- Cummings JR, Wen H, Ko M, Druss BG. Race/ethnicity and geographic access to Medicaid substance use disorder treatment facilities in the United States. JAMA Psychiatry. 2014;71:190–96. doi:https://doi.org/10.1001/jamapsychiatry.2013.3575.
- Lewer D, Freer J, King E, Larney S, Degenhardt L, Tweed EJ, Hope VD, Harris M, Millar T, Hayward A, et al. Frequency of healthcare utilisation by adults who use illicit drugs: a systematic review and meta-analysis. Addiction. 2020;115:1011–23. doi: https://doi.org/10.1111/add.14892.
- Mattson ME Emergency department visits involving methamphetamine: 2007 to 2011. In The CBHSQ Report; Rockville (MD), 2013, 1–7.
- Lanyon C, Nambiar D, Higgs P, Dietze P, Five-year QB. Changes in methamphetamine use, dependence, and remission in a community-recruited cohort. J Addict Med. 2019;13:159–65. doi:https://doi.org/10.1097/ADM.0000000000000469.
- Brecht ML, Lovinger K, Herbeck DM, Urada D. Patterns of treatment utilization and methamphetamine use during first 10 years after methamphetamine initiation. J Subst Abuse Treat. 2013;44:548–56. doi:https://doi.org/10.1016/j.jsat.2012.12.006.
- McKetin R, Degenhardt L, Shanahan M, Baker AL, Lee NK, Lubman DI. Health service utilisation attributable to methamphetamine use in Australia: patterns, predictors and national impact. Drug Alcohol Rev. 2018;37:196–204. doi:https://doi.org/10.1111/dar.12518.
- Hagedorn HJ, Noorbaloochi S, Bangerter A, Stitzer ML, Kivlahan D. Health care cost trajectories in the year prior to and following intake into Veterans Health Administration outpatient substance use disorders treatment. J Subst Abuse Treat. 2017;79:46–52. doi:https://doi.org/10.1016/j.jsat.2017.05.013.
- Salo R, Flower K, Kielstein A, Leamon MH, Nordahl TE, Galloway GP. Psychiatric comorbidity in methamphetamine dependence. Psychiatry Res. 2011;186:356–61. doi:https://doi.org/10.1016/j.psychres.2010.09.014.
- Lin SK, Ball D, Hsiao CC, Chiang YL, Ree SC, Chen CK. Psychiatric comorbidity and gender differences of persons incarcerated for methamphetamine abuse in Taiwan. Psychiatry Clin Neurosci. 2004;58:206–12. doi:https://doi.org/10.1111/j.1440-1819.2003.01218.x.
- Liu CY, Hung YT, Chuang YL, Chen YJ, Weng WS, Liu JS, Liang KY. Incorporating development stratification of Taiwan townships into sampling design of large scale health interview survey. J Health Manage. 2006;4:1–22.
- Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83. doi:https://doi.org/10.1016/0021-9681(87)90171-8.
- WHO Collaborating. Centre for drug statistic methodology. ATC index with DDDs. Oslo: WHO; 2018.
- Yimsaard P, Maes MM, Verachai V, Kalayasiri R. Pattern of methamphetamine use and the time lag to methamphetamine dependence. J Addict Med. 2018;12:92–98. doi:https://doi.org/10.1097/ADM.0000000000000371.
- Kittirattanapaiboon P, Srikosai S, Wittayanookulluk A. Methamphetamine use and dependence in vulnerable female populations. Curr Opin Psychiatry. 2017;30:247–52. doi:https://doi.org/10.1097/YCO.0000000000000335.
- Kamp F, Proebstl L, Hager L, Schreiber A, Riebschlager M, Neumann S, Straif M, Schacht-Jablonowsky M, Manz K, Soyka M, et al. Effectiveness of methamphetamine abuse treatment: predictors of treatment completion and comparison of two residential treatment programs. Drug Alcohol Depend. 2019;201:8–15. doi:https://doi.org/10.1016/j.drugalcdep.2019.04.010.
- McKetin R, Leung J, Stockings E, Huo Y, Foulds J, Lappin JM, Cumming C, Arunogiri S, Young JT, Sara G, et al. Mental health outcomes associated with of the use of amphetamines: a systematic review and meta-analysis. EClinicalMedicine. 2019;16:81–97. doi:https://doi.org/10.1016/j.eclinm.2019.09.014.
- Lorvick J, Browne EN, Lambdin BH, Comfort M. Polydrug use patterns, risk behavior and unmet healthcare need in a community-based sample of women who use cocaine, heroin or methamphetamine. Addict Behav. 2018;85:94–99. doi:https://doi.org/10.1016/j.addbeh.2018.05.013.
- Callaghan RC, Cunningham JK, Allebeck P, Arenovich T, Sajeev G, Remington G, Boileau I, Kish SJ. Methamphetamine use and schizophrenia: a population-based cohort study in California. Am J Psychiatry. 2012;169:389–96. doi:https://doi.org/10.1176/appi.ajp.2011.10070937.
- Kittirattanapaiboon P, Mahatnirunkul S, Booncharoen H, Thummawomg P, Dumrongchai U, Chutha W. Long-term outcomes in methamphetamine psychosis patients after first hospitalisation. Drug Alcohol Rev. 2010;29:456–61. doi:https://doi.org/10.1111/j.1465-3362.2010.00196.x.
- Farnia V, Farshchian F, Farshchian N, Alikhani M, Sadeghi Bahmani D, Brand S. Comparisons of voxel-based morphometric brain volumes of individuals with methamphetamine-induced psychotic disorder and schizophrenia spectrum disorder and healthy controls. Neuropsychobiology. 2020;79:170–178.
- Valvassori SS, Mariot E, Varela RB, Bavaresco DV, Dal-Pont GC, Ferreira CL, Andersen ML, Tye SJ, Quevedo J. The role of neurotrophic factors in manic-, anxious- and depressive-like behaviors induced by amphetamine sensitization: implications to the animal model of bipolar disorder. J Affect Disord. 2019;245:1106–13. doi:https://doi.org/10.1016/j.jad.2018.10.370.
- Post RM, Kalivas P. Bipolar disorder and substance misuse: pathological and therapeutic implications of their comorbidity and cross-sensitisation. Br J Psychiatry. 2013;202:172–76. doi:https://doi.org/10.1192/bjp.bp.112.116855.
- Malhi GS, Byrow Y, Bassett D, Boyce P, Hopwood M, Lyndon W, Mulder R, Porter R, Singh A, Murray G. Stimulants for depression: on the up and up? Aust N Z J Psychiatry. 2016;50:203–07. doi:https://doi.org/10.1177/0004867416634208.
- Turner S, Mota N, Bolton J, Sareen J. Self-medication with alcohol or drugs for mood and anxiety disorders: a narrative review of the epidemiological literature. Depress Anxiety. 2018;35:851–60. doi:https://doi.org/10.1002/da.22771.
- Wang TY, Fan TT, Bao YP, Li XD, Liang CM, Wang RJ, Ma J, Han Y, Meng SQ, Wu P, et al. Pattern and related factors of cognitive impairment among chronic methamphetamine users. Am J Addict. 2017;26:145–51. doi:https://doi.org/10.1111/ajad.12505.
- Sabrini S, Wang GY, Lin JC, Ian JK, Curley LE. Methamphetamine use and cognitive function: a systematic review of neuroimaging research. Drug Alcohol Depend. 2019;194:75–87. doi:https://doi.org/10.1016/j.drugalcdep.2018.08.041.
- Chen CK, Lin SK, Chen YC, Huang MC, Chen TT, Ree SC, Wang LJ. Persistence of psychotic symptoms as an indicator of cognitive impairment in methamphetamine users. Drug Alcohol Depend. 2015;148:158–64. doi:https://doi.org/10.1016/j.drugalcdep.2014.12.035.
- Tsai H, Lee J, Hedlin H, Zamanian RT. de Jesus Perez VA. Methamphetamine use association with pulmonary diseases: a retrospective investigation of hospital discharges in California from 2005 to 2011. ERJ Open Res. 2019;5:00017–2019. doi:https://doi.org/10.1183/23120541.00017-2019.
- Salamanca SA, Sorrentino EE, Nosanchuk JD, Martinez LR. Impact of methamphetamine on infection and immunity. Front Neurosci. 2014;8:445.